La chaîne d'options affiche les données clés des options sur actions de Relmada Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Relmada Therapeutics..

Relmada Therapeutics (NASDAQ:RLMD) Stock, Chaîne d'Options

Relmada Therapeutics

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics Inc

Earnings

Press Releases

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

News

Management

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

Health Care

Relmada Issues Mid-Year CEO Letter to Shareholders

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

Events

Sidoti Events, LLC's Virtual September Small-Cap Conference

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

ASTE

CMCO

CRAI

CSE:BOIL

DAKT

DYAI

FBRT

FFAI

FMAO

FSTR

GAIA

GAMI

GLDD

HIPO

HITI

HURN

HWKN

IDCC

IIIN

KELYA

KFRC

KGEI

KINS

LICT

LXFR

MAGN

MATV

MPTI

MTUS

NMTC

ONIT

OPRT

OSPN

PKOH

PLCE

PLUS

PSTL

RELL

RLMD

ROCK

SLVM

STRR

UXIN

VNCE

VREX

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Assertio Holdings

Biote

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Cardiol Therapeutics Inc. - Class A Common Shares

Cardiol Therapeutics

Hyperion DeFi

ImageneBio

Intercure

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

NRX Pharmaceuticals

Nasus Pharma

Nutriband

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Pliant Therapeutics

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

Quantum BioPharma

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

Scilex Holding

Sol-Gel Technologies Ltd. - Ordinary Shares

Sol-Gel Technologies

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Talphera

Tvardi Therapeutics

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Veru

Mizuho

Leerink Partners

Jefferies

Goldman Sachs

RELMADA THERAPEUTICS by Relmada Therapeutics, Inc.

Comments

Relmada Therapeutics

Relmada Therapeutics (RLMD) Options

Relmada Therapeutics (NASDAQ:RLMD) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL